Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096725 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL30353978 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL26243844 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL12085049 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL1811839 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL185267 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL30660898 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL12082047 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL7154268 | 1.00 | LGALS3 (0.44) | LGALS3CA1CA2CA9PYGB | |
| SCHEMBL29065825 | 0.98 | LGALS3 (0.43) | LGALS3CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688058-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190254978-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-10 | — | — | US | disclosed |
| EP-2098533-A1 | Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098534-A1 | Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy | PHARMACHEMIE B.V. (NL) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190254978-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, DDO, SLC6A3 | LGALS3 2959/4885CA1 2885/4885CA2 4333/4885 |
| US-20090227617-A1 | Esters Of Glucuronide Prodrugs Of Anthracyclines And Method Of Preparation And Use In Tumor-Selective Chemotherapy | GALE, UGGT1, UGT1A3 | LGALS3 1108/4885CA1 829/4885CA2 3627/4885 |
| US-10688058-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, DDO, SLC6A3 | LGALS3 2959/4885CA1 2885/4885CA2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.